P-Glycoprotein Function at the Blood–Brain Barrier Imaged Using ¹¹C-N-Desmethyl-Loperamide in Monkeys

¹ Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland
² PET Department, Clinical Center, National Institutes of Health, Bethesda, Maryland

^* To whom correspondence should be addressed. E-mail: liowj{at}mail.nih.gov.

	Abstract

¹¹C-Loperamide is an avid substrate for P-glycoprotein (P-gp), but it is rapidly metabolized to ¹¹C-N-desmethyl-loperamide (¹¹C-dLop), which is also a substrate for P-gp and thereby contaminates the radioactive signal in the brain. Should further demethylation of ¹¹C-dLop occur, radiometabolites with low entry into the brain are generated. Therefore, we evaluated the ability of ¹¹C-dLop to quantify the function of P-gp at the blood–brain barrier in monkeys. Methods: Six monkeys underwent 12 PET scans of the brain, 5 at baseline and 7 after pharmacologic blockade of P-gp. A subset of monkeys also underwent PET scans with ¹⁵O-water to measure cerebral blood flow. To determine whether P-gp blockade affected peripheral distribution of ¹¹C-dLop, we measured whole-body biodistribution in 4 monkeys at baseline and after P-gp blockade. Results: The concentration of ¹¹C-dLop in the brain was low under baseline conditions and increased 5-fold after P-gp blockade. This increase was primarily caused by an increased rate of entry into the brain rather than a decreased rate of removal from the brain. With P-gp blockade, uptake of radioactivity among brain regions correlated linearly with blood flow, suggesting a high single-pass extraction. After correction for cerebral blood flow, the uptake of ¹¹C-dLop was fairly uniform among brain regions, suggesting that the function of P-gp is fairly uniformly distributed in the brain. On whole-body imaging, P-gp blockade significantly affected distribution of radioactivity only to the brain and not to other visually identified source organs. The effective dose estimated for humans was approximately 9 µSv/MBq. Conclusion: PET with ¹¹C-dLop can quantify P-gp function at the blood–brain barrier in monkeys. The single-pass extraction of ¹¹C-dLop is high and requires correction for blood flow to accurately measure the function of this efflux transporter. The low uptake at baseline and markedly increased uptake after P-gp blockade suggest that ¹¹C-dLop will be useful to measure a wide range of P-gp functions at the blood–brain barrier in humans.

Key Words: molecular imaging, radiotracer tissue kinetics, P-glycoprotein, loperamide, PET

This article has been cited by other articles:

				C. C. Wagner, M. Bauer, R. Karch, T. Feurstein, S. Kopp, P. Chiba, K. Kletter, W. Loscher, M. Muller, M. Zeitlinger, et al. A Pilot Study to Assess the Efficacy of Tariquidar to Inhibit P-glycoprotein at the Human Blood-Brain Barrier with (R)-11C-Verapamil and PET J. Nucl. Med., December 1, 2009; 50(12): 1954 - 1961. [Abstract] [Full Text] [PDF]

				N. Seneca, S. S. Zoghbi, J.-S. Liow, W. Kreisl, P. Herscovitch, K. Jenko, R. L. Gladding, A. Taku, V. W. Pike, and R. B. Innis Human Brain Imaging and Radiation Dosimetry of 11C-N-Desmethyl-Loperamide, a PET Radiotracer to Measure the Function of P-Glycoprotein J. Nucl. Med., May 1, 2009; 50(5): 807 - 813. [Abstract] [Full Text] [PDF]